Why RoosterBio?

Our Mission: Fuel the Rapid Implementation of Scalable Advanced Therapies

At RoosterBio, we are experts in radically simplifying the use of adult human mesenchymal stem/stromal cells (hMSCs) and extracellular vesicles (EVs) to propel the commercialization of therapeutic technologies. By enabling living cells to become more affordable at the lowest cost per million cells with industry-leading quality, we make them easier to access and much simpler to incorporate into product development efforts, leading to the rapid acceleration of products coming to market that incorporate these technologies.

Our Solutions to Industry Challenges

High-quality hMSCs have traditionally been a scarce resource in the field, being expensive, time-consuming to grow, and requiring the skills of highly trained scientists to obtain quality cells. We are driving the transition of hMSCs from a scarce resource into an abundant resource, increasing their availability and decreasing the complexity required to incorporate them into products.

RoosterBio’s translation-friendly products include high-volume, well-characterized adult hMSCs, bioprocess media systems, genetic engineering tools, and EV production solutions paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing. RoosterBio has simplified and standardized how living cells are purchased, expanded, and used in development, leading to marked time and cost savings for customers. We have demonstrated that our cells can be used directly out of thaw – eliminating the expansion step from initiating an experiment. Our innovative solutions are ushering in a new era of productivity and standardization for advanced therapies, accelerating the road to discovery.

Company FAQs

RoosterBio was founded in 2013 with the intention to de-bottleneck and accelerate the adult mesenchymal stem/stromal cell industry. RoosterBio launched manufacturing operations in October 2013 and started shipping cell and media products to customers in February 2014. We have since served hundreds of global customers from North America to Europe to Asia. We are driven by our client’s success and creating a world where safe and effective regenerative medicines are rapidly developed and widely available on a global scale.

Why the name RoosterBio?

Roosters proclaim the dawn of every new day, and RoosterBio is here to proudly proclaim the dawn of a new day for scalable advanced therapies.

Why was RoosterBio created?

RoosterBio was created to accelerate the biologics and biofabrication revolution, much in the same way that 3D printers drove the local-maker movement. We believe that if we can radically simplify the use of biotechnology and help make living cells into an abundant resource while driving the cost of MSCs from >$1,000 to less than $10 per million cells, we will greatly accelerate the development of next-generation therapeutics, medical devices, and even consumer products, enhancing the lives of patients around the world.

What is biofabrication?

Biofabrication is the creation of advanced biological models, medical therapeutic products, and non-medical biological systems.

What is the relationship between MSCs and the field of regenerative medicine?

Due to their tremendous therapeutic potential, the trend of MSC technology being incorporated into regenerative therapies will continue, and there is a strong need for affordable, abundant, and extremely well-characterized MSC products to enable product development and successful clinical translation. New technologies such as bioprinting, tissue engineering, extracellular vesicles/exosomes, gene editing, and, of course, cell manufacturing will continue to propel regenerative medicine forward and further necessitate the need for the availability of large numbers of clinically-translatable MSCs.